Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$5.70
-4.4%
$6.24
$5.20
$15.60
$10.94M0.8911,804 shs15,531 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.00
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
C$0.00
C$0.12
C$2.50
C$21.27MN/A68,686 shs239,293 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-3.72%+1.53%-2.30%-13.62%-60.23%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.0339 of 5 stars
3.22.00.00.02.73.31.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.33
Hold$50.00777.19% Upside
CZX
Canada Zinc Metals
0.00
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
4.00
Strong BuyN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TRL, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
5/13/2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$25.00 ➝ $20.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.69M1.42N/AN/A$29.89 per share0.19
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
C$407.64M0.00N/A0.77C$0.38 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
N/AC$6.340.04N/A0.86N/AN/AN/AN/A

Latest TRL, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$6.40N/AN/AN/A$0.82 millionN/A
5/12/2025Q1 2025
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
C$1.31704.17%N/A20.69%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.48
3.13
3.13
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
N/A
5.92
3.87
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.92 million1.33 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable
Trilogy International Partners Inc. stock logo
TRL
Trilogy International Partners
70,00088.63 millionN/ANot Optionable

Recent News About These Companies

Trilogy International Partners Inc TRL.H
Trilogy International Ltd (TIL)
Trilogy International Partners GAAP EPS of -$0.03

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$5.70 -0.26 (-4.36%)
Closing price 03:59 PM Eastern
Extended Trading
$5.70 0.00 (0.00%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals CVE:CZX

C$0.31 +0.31 (+∞)
As of 05/4/2018

Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.

Trilogy International Partners stock logo

Trilogy International Partners TSE:TRL

Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services in New Zealand, Bolivia, and internationally. It offers prepaid and postpaid payment plans, including local, international long distance, and roaming services to customers and international visitors roaming on its networks. The company also provides fixed broadband communications to residential and enterprise customers, as well as a range of mobile and fixed line services in New Zealand and Australia; and fixed public telephony and wireless broadband services in Bolivia. As of December 31, 2021, it had a distribution network of approximately 13 company owned stores, 170 dealers, and 8,300 other dealer points of presence in Bolivia; and a distribution network of approximately 20 company owned retail stores, 40 independent dealers, and 2,500 points of sale through national retail chains and grocery stores in New Zealand. The company's services cover an aggregate population of 16.8 million users. It also provides services through its online self-service store in New Zealand; and operates under the Viva brand name in Bolivia. Trilogy International Partners Inc. was founded in 1982 and is headquartered in Bellevue, Washington.